基本信息:
- 专利标题： ANTI-CD28 HUMANIZED ANTIBODIES FORMULATED FOR ADMINISTRATION TO HUMANS
- 申请号：EP16822423.6 申请日：2016-12-15
- 公开(公告)号：EP3390450A1 公开(公告)日：2018-10-24
- 发明人： VANHOVE, Bernard
- 申请人： OSE Immunotherapeutics
- 申请人地址： 22 Boulevard Benoni Goullin 44200 Nantes FR
- 专利权人： OSE Immunotherapeutics
- 当前专利权人： OSE IMMUNOTHERAPEUTICS
- 当前专利权人地址： OSE IMMUNOTHERAPEUTICS
- 代理机构： Wise, Daniel Joseph
- 优先权： EP15200281 20151215; EP16306537 20161122
- 国际公布： WO2017103003 20170622
- 主分类号： C07K16/28
- IPC分类号： C07K16/28 ; A61P37/06
摘要：
The present invention pertains to a novel and advantageous dosage regimen for a humanized pegylated monovalent anti-CD28 Fab′ antibody fragment, called “FR104”. This dosage regimen consists of between 0.05 and 1.5 mg/kg body weight of FR104, at a dosing schedule of once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks or once every 6 weeks, once every 7 weeks, once every 8 weeks or once every more than 8 weeks.
公开/授权文献:
IPC结构图谱:
| C | 化学；冶金 |
| --C07 | 有机化学 |
| ----C07K | 肽 |
| ------C07K16/00 | 免疫球蛋白，例如，单克隆或多克隆抗体 |
| --------C07K16/18 | .来自动物或人的抵抗物质 |
| ----------C07K16/28 | ..抗受体，细胞表面抗原或细胞表面决定因子 |